Psoriatic Arthritis
Conference Coverage
International expert group agrees on redefining psoriasis severity
“What we came up with is a very sensible approach to defining whether patients should get either topical or systemic therapy.”
Conference Coverage
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis
“The guidelines don’t give full credit to the anti–IL-17 agents.”
Conference Coverage
Expanded indications likely for apremilast
“My prediction is apremilast will have efficacy in children and teenagers comparable to what it has in adults.”
From the Journals
TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possible
TNFI-induced psoriasis improved or resolved with topical medications alone in 63.5% of patients.
Conference Coverage
Tildrakizumab for psoriasis shows durable efficacy over 5 years
Few left long-term extension study because of adverse events or loss of efficacy.
Conference Coverage
Chronic inflammatory diseases vary widely in CHD risk
The highest coronary heart disease risks linked to inflammation are seen in SLE and systemic sclerosis, conditions that aren’t included in...
Conference Coverage
Methotrexate users need tuberculosis tests in high-TB areas
Those taking corticosteroids or other immunosuppressants are at particularly high risk, a systematic review of literature finds.
Conference Coverage
COVID-19 risks in rheumatic disease remain unclear
Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more...
Conference Coverage
Topical tapinarof effective in pivotal psoriasis trials
Efficacy was comparable with potent topical corticosteroids, but without the side-effects baggage.
Conference Coverage
Biologics may protect psoriasis patients against severe COVID-19
Preliminary evidence suggests biologics prevent the fearsome COVID-19 late cytokine storm.
Conference Coverage
Mirikizumab beats placebo, secukinumab for psoriasis
If approved, mirikizumab, which binds the p19 subunit of IL-23, would join three other IL-23 drugs already marketed in the United States for...